UNSPSC 51293005: Butriptyline

This classification denotes an antidepressant agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z22441975X, chemically known as 10,11-dihydro-n,n,beta-trimethyl-5h-dibenzo(a,d)cycloheptene-5-propylamine but generally known as butriptyline, which bears US NIH Compound Identifier 21772. Butriptyline most often comes in base, butriptylene, and hydrochloride forms.

UNSPSC 51293005 Butriptyline is a Commodity code, yet recent state and local opportunities tagged under it show minimal alignment with that specific pharmaceutical product. Instead, the code captures broader pharmaceutical procurement activity spanning naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local buying under this code reflects public health emergency response, pharmacy benefit program modernization, and cooperative purchasing arrangements that extend across health departments, state HHS commissions, and multistate procurement alliances rather than traditional commodity-line purchasing.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2026, as part of a two-year contract with one-year renewal option through the county's e-Procurement Portal. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The MMCAP RFP requires vendor compliance with current Good Manufacturing Practices, Drug Supply Chain Security Act certification, and maintains a two-year initial term with optional extensions through June 30, 2028.